Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acrivon Therapeutics, Inc.ACRV · Entity 573 | Director | June 17, 2026 | June 22, 2026 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Chief Scientific Officer | March 29, 2022 | March 31, 2022 |
| Nasus Pharma LtdNSRX · Entity 7254 | Director | March 18, 2026 | March 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acrivon Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.52 · Expires 2036-06-16 | Direct | 20,275 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 20,275 · Balance 20,275 F1: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.
Karyopharm Therapeutics Inc.
Report date March 29, 2022 · Filed March 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 958,131 |
Reported balance
After 2022-03-29 transaction · row 1
1 source rowRow 1 · 2022-03-29 · Grant · Acquired 60,000 · Balance 958,131 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.33 · Expires 2032-03-28 | Direct | 90,000 |
Reported balance
After 2022-03-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-29 · Grant · Acquired 90,000 · Balance 90,000 F2: This option was granted on March 29, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 713,757 |
Reported balance
Holding disclosure · report date 2022-03-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 713,757 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.
F2: This option was granted on March 29, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Nasus Pharma Ltd
Report date March 18, 2026 · Filed March 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.38 · Expires 2035-12-11 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Options to purchase 10,000 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on December 11, 2025, with 2.0833% of the total grant vesting monthly following December 11, 2025. As of March 18, 2026, 10,000 options remain outstanding, of which 625 are vested and exercisable, at an exercise price of $5.38 per share, expiring December 11, 2035. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 10,000 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on December 11, 2025, with 2.0833% of the total grant vesting monthly following December 11, 2025. As of March 18, 2026, 10,000 options remain outstanding, of which 625 are vested and exercisable, at an exercise price of $5.38 per share, expiring December 11, 2035.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2020 Filed Feb 12, 2020 21:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-008729 · doc4.xml · derivative · entry 5 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,303 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $16.93 | $169,327.00 |
DisclosureSEC source: 0001209191-20-008729 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743,506 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.793 to $17.21, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-20-008729 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:16 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantRestricted Stock Units · Derivative | 57,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007496 · doc4.xml · derivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 57,200 Underlying: Common Stock · 57,200 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:16 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantRestricted Stock Units · Derivative | 57,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007496 · doc4.xml · derivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,200 Underlying: Common Stock · 57,200 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:16 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 153,500 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007496 · doc4.xml · derivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 153,500 Underlying: Common Stock · 153,500 shares Expires 2030-02-04 F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:16 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 153,500 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007496 · doc4.xml · derivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,500 Underlying: Common Stock · 153,500 shares Expires 2030-02-04 F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 22:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-003086 · doc4.xml · derivative · entry 8 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 386,061 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F9 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 22:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $19.19 | $191,880.00 |
DisclosureSEC source: 0001209191-20-003086 · doc4.xml · nonDerivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 542,139 F4 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F6 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.885 to $19.34, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 22:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-20-003086 · doc4.xml · nonDerivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 552,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · balance_after: Reflects the transfer of 12,372 shares from the Michael G. Kauffman 2016 Qualified Annuity Trust (the "Spouse's GRAT") to the spouse of the reporting person on December 12, 2019. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 22:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-003086 · doc4.xml · derivative · entry 7 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,303 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 22:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $18.57 | $185,705.00 |
DisclosureSEC source: 0001209191-20-003086 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743,506 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.34 to $18.82, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 22:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-20-003086 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Reflects the transfer of 12,372 shares from the Sharon Shacham 2016 Qualified Annuity Trust (the "GRAT") to the reporting person on December 12, 2019. Read SEC document |
| December 19, 2019 Filed Jan 10, 2020 22:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GiftCommon Stock | 17,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-003086 · doc4.xml · nonDerivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse's GRAT Disclosed balance after: 0 F8 · ownership.nature: Upon termination of the Spouse's GRAT, 17,313 shares held by the Spouse's GRAT were transferred to a trust, the beneficiaries of which share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by such individuals, and this report should not be deemed an admission that the reporting person is the beneficial owner of such individuals' shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 19, 2019 Filed Jan 10, 2020 22:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GiftCommon Stock | 17,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-003086 · doc4.xml · nonDerivative · entry 5 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By GRAT Disclosed balance after: 0 F7 · ownership.nature: Upon termination of the GRAT, 17,313 shares held by the GRAT were transferred to a trust, the beneficiaries of which share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by such individuals, and this report should not be deemed an admission that the reporting person is the beneficial owner of such individuals' shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 22:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-19-060072 · doc4.xml · derivative · entry 8 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 396,061 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F7 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 22:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $15.99 | $159,896.00 |
DisclosureSEC source: 0001209191-19-060072 · doc4.xml · nonDerivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 529,767 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.61 to $16.45, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 22:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-19-060072 · doc4.xml · nonDerivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 539,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 22:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-19-060072 · doc4.xml · derivative · entry 7 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,303 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 22:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $17.02 | $170,210.00 |
DisclosureSEC source: 0001209191-19-060072 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,134 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.75 to $17.58, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 22:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-19-060072 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 741,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 21:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-19-056027 · doc4.xml · derivative · entry 8 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 406,061 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F7 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 21:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $14.76 | $147,610.00 |
DisclosureSEC source: 0001209191-19-056027 · doc4.xml · nonDerivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 529,767 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $14.65 to $14.835, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 21:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-19-056027 · doc4.xml · nonDerivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 539,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 21:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-19-056027 · doc4.xml · derivative · entry 7 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,303 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 21:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $14.63 | $146,254.00 |
DisclosureSEC source: 0001209191-19-056027 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,134 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $14.22 to $14.90, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 21:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-19-056027 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 741,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-19-055170 · doc4.xml · derivative · entry 8 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 416,061 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-19-055170 · doc4.xml · derivative · entry 7 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,303 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $12.00 | $120,000.00 |
DisclosureSEC source: 0001209191-19-055170 · doc4.xml · nonDerivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 529,767 F2 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-19-055170 · doc4.xml · nonDerivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 539,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $12.00 | $120,000.00 |
DisclosureSEC source: 0001209191-19-055170 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,134 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:10 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-19-055170 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 741,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:54 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-19-049868 · doc4.xml · derivative · entry 8 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 426,061 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:54 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-19-049868 · doc4.xml · derivative · entry 7 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,303 Underlying: Common Stock · 10,000 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:54 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $12.00 | $120,000.00 |
DisclosureSEC source: 0001209191-19-049868 · doc4.xml · nonDerivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 529,767 F2 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:54 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-19-049868 · doc4.xml · nonDerivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 539,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:54 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $12.00 | $120,000.00 |
DisclosureSEC source: 0001209191-19-049868 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,134 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:54 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $4.75 | $47,520.00 |
DisclosureSEC source: 0001209191-19-049868 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 741,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:25 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantRestricted Stock Units · Derivative | 87,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011079 · doc4.xml · derivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 87,200 Underlying: Common Stock · 87,200 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:25 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantRestricted Stock Units · Derivative | 87,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011079 · doc4.xml · derivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,200 Underlying: Common Stock · 87,200 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:25 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 231,200 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001209191-19-011079 · doc4.xml · derivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 231,200 Underlying: Common Stock · 231,200 shares Expires 2029-02-14 F1 · derivative.exercise_date: This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:25 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 231,200 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001209191-19-011079 · doc4.xml · derivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,200 Underlying: Common Stock · 231,200 shares Expires 2029-02-14 F1 · derivative.exercise_date: This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:37 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-19-003059 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,357 Underlying: Common Stock · 12,500 shares Expires 2020-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on October 22, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:37 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 12,500 | $10.23 | $127,823.75 |
DisclosureSEC source: 0001209191-19-003059 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 731,134 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.45, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:37 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 12,500 | $0.03 | $412.50 |
DisclosureSEC source: 0001209191-19-003059 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Reflects the transfer of 17,624 shares from the Sharon Shacham 2016 Qualified Annuity Interest Trust (the "GRAT") to the reporting person on December 10, 2018. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 21:28 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001209191-18-061765 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,857 Underlying: Common Stock · 12,500 shares Expires 2020-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on October 22, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 21:28 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 12,500 | $10.11 | $126,422.50 |
DisclosureSEC source: 0001209191-18-061765 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,510 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.275, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 21:28 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 12,500 | $0.03 | $412.50 |
DisclosureSEC source: 0001209191-18-061765 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 21:20 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 9,600 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-18-059990 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 436,061 Underlying: Common Stock · 9,600 shares Expires 2023-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F4 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.